1 / 36

Precision Medicine Market 2020-2030

The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.

bisreports
Download Presentation

Precision Medicine Market 2020-2030

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Precision Medicine Market Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape: Analysis and Forecast: 2020-2030 August-2020 TOC

  2. Global Precision Medicine Market BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2020 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research 2

  3. Global Precision Medicine Market T Table of able of C Contents ontents 1.Product Definition .................................................................................................... 48 1.1 Inclusion and Exclusion ................................................................................. 48 2.Research Scope ........................................................................................................ 49 2.1 2.2 2.3 2.4 Scope of Study ................................................................................................ 49 Key Questions Answered in the Report ........................................................ 51 Global Precision Medicine Market: Research Methodology ........................ 51 Criteria for Company Profiling ....................................................................... 52 3.Research Methodology ............................................................................................ 54 3.1 3.2 3.3 Primary Data Sources ..................................................................................... 54 Secondary Data Sources ................................................................................ 55 Market Estimation Model ................................................................................ 55 4.Global Precision Medicine Market Overview.......................................................... 58 4.1 4.2 Market Definition ............................................................................................. 58 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine ........................................................................................................... 59 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy ......................................................................... 61 Initiatives and Programs................................................................................. 62 Precision Medicine: Enabling Technologies and Applications ................... 66 4.5.1 Innovators ......................................................................................... 67 4.5.1.1 3D DNA Printing ............................................................................ 67 4.5.1.1.1 Introduction ............................................................................................ 67 4.5.1.1.2 Role of 3D DNA Printing......................................................................... 68 4.5.1.2 RNA-Seq ....................................................................................... 68 4.5.1.2.1 Introduction ............................................................................................ 68 4.5.1.2.2 Role of RNA-Seq in Precision Medicine ................................................. 68 4.5.1.2.3 Key Players ............................................................................................ 68 4.5.1.3 4D Molecular Imaging ................................................................... 69 4.5.1.3.1 Introduction ............................................................................................ 69 4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine .............................. 69 4.3 4.4 4.5 All rights reserved at BIS Research 3

  4. Global Precision Medicine Market 4.5.1.3.3 4.5.2 4.5.2.1 4.5.2.1.1 4.5.2.1.2 4.5.2.1.3 4.5.2.2 4.5.2.2.1 4.5.2.2.2 4.5.2.2.3 4.5.2.3 4.5.2.3.1 4.5.2.3.2 4.5.2.3.3 4.5.3 4.5.3.1 4.5.3.1.1 4.5.3.1.2 4.5.3.1.3 4.5.3.2 4.5.3.2.1 4.5.3.2.2 4.5.3.2.3 4.5.3.3 4.5.3.3.1 4.5.3.3.2 4.5.3.3.3 4.5.3.4 4.5.3.4.1 4.5.3.4.2 4.5.3.4.3 4.5.3.5 4.5.3.5.1 4.5.3.5.2 Key Players ............................................................................................ 69 Early Adopters .................................................................................. 70 CRISPR ........................................................................................ 70 Introduction ............................................................................................ 70 Role of CRISPR in Precision Medicine ................................................... 70 Key Players ............................................................................................ 71 Blockchain ..................................................................................... 71 Introduction ............................................................................................ 71 Role of Blockchain in Precision Medicine ............................................... 71 Key Players ............................................................................................ 72 Imaging Informatics ....................................................................... 72 Introduction ............................................................................................ 72 Role of Imaging Informatics in Precision Medicine ................................. 72 Key Players ............................................................................................ 73 Early Majority .................................................................................... 73 Artificial Intelligence (AI) ................................................................ 73 Introduction ............................................................................................ 73 Role of Artificial Intelligence in Precision Medicine ................................. 73 Key Players ............................................................................................ 74 Circulating Free DNA (cfDNA)....................................................... 74 Introduction ............................................................................................ 74 Role of cfDNA in Precision Medicine ...................................................... 74 Key Players ............................................................................................ 75 Big Data ........................................................................................ 75 Introduction ............................................................................................ 75 Role of Big Data in Precision Medicine ................................................... 75 Key Players ............................................................................................ 76 Next-Generation Sequencing (NGS) ............................................. 77 Introduction ............................................................................................ 77 Role of NGS in Precision Medicine ........................................................ 77 Key Players ............................................................................................ 77 Health Informatics ......................................................................... 78 Introduction ............................................................................................ 78 Role of Health Informatics in Precision Medicine .................................... 78 All rights reserved at BIS Research 4

  5. Global Precision Medicine Market 4.5.3.5.3 4.5.3.6 4.5.3.6.1 4.5.3.6.2 4.5.3.6.3 4.5.4 4.5.4.1 4.5.4.1.1 4.5.4.1.2 4.5.4.1.3 4.5.4.2 4.5.4.2.1 4.5.4.2.2 COVID-19 Impact on the Global Precision Medicine Market ....................... 83 Key players ............................................................................................ 79 Bioinformatics................................................................................ 79 Introduction ............................................................................................ 79 Role of Bioinformatics in Precision Medicine .......................................... 80 Key Players ............................................................................................ 80 Late Majority ..................................................................................... 80 Polymerase Chain Reactions (PCR) ............................................. 80 Introduction ............................................................................................ 80 Role of PCR in Precision Medicine ......................................................... 81 Key players ............................................................................................ 81 Microarray ..................................................................................... 81 Role of Microarray in Precision Medicine ............................................... 82 Key Players ............................................................................................ 83 4.6 5.Market Dynamics ...................................................................................................... 85 5.1 5.2 Overview .......................................................................................................... 85 Market Drivers ................................................................................................. 87 5.2.1 Advancement of Sequencing Technologies .................................. 87 5.2.2 Rising Prevalence of Chronic Diseases ......................................... 89 5.2.3 Growing Demand for Preventive Care ............................................ 91 5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention ......................................................................................... 92 5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test ................................................................. 92 5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe ................................................................................................. 93 Market Restraints ............................................................................................ 94 5.3.1 Unified Framework for Data Integration ......................................... 94 5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction ......................................................................................... 94 5.3.3 Lack of Robust Reimbursement Landscape .................................. 95 5.3.4 Regulatory Hurdles .......................................................................... 96 Market Opportunities ...................................................................................... 98 5.4.1 Targeted Gene Therapy ................................................................... 98 5.3 5.4 All rights reserved at BIS Research 5

  6. Global Precision Medicine Market 5.4.2 5.4.3 Expansion into the Emerging Markets ........................................... 99 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry .......................................................... 100 6.Industry Insights ..................................................................................................... 101 6.1 6.2 6.3 6.4 6.5 6.6 Patent Analysis ............................................................................................. 101 Legal Requirements and Regulations ......................................................... 102 Pipeline Analysis ........................................................................................... 104 Legal Requirements and Framework by the FDA ....................................... 112 Legal Requirements and Framework by the EMA ...................................... 115 Legal Requirements and Framework by the MHLW ................................... 116 7.Competitive Landscape ......................................................................................... 118 7.1 Synergistic Activities .................................................................................... 119 7.1.1 Product launches, Enhancements, and Upgradation .................. 121 7.1.2 Product Approvals ......................................................................... 122 7.1.3 Mergers and Acquisitions .............................................................. 123 7.1.4 Business Expansion ...................................................................... 125 Market Share Analysis .................................................................................. 126 7.2.1 Market Share Analysis by Applied Sciences, 2019...................... 127 7.2.2 Market Share Analysis by Precision Diagnostics, 2019 .............. 129 7.2.3 Market Share Analysis by Precision Therapeutics, 2019 ............ 131 7.2.4 Market Share Analysis by Digital Health and IT, 2019 ................. 133 7.2 8.Global Precision Medicine Market (by Ecosystem) ............................................. 135 8.1 8.2 Overview ........................................................................................................ 135 Applied Sciences .......................................................................................... 138 8.2.1 Genomics ........................................................................................ 141 8.2.2 Global Precision Medicine Genomics Market (by Technology) .................................................................................... 143 8.2.2.1 Polymerase Chain Reaction (PCR) ............................................. 144 8.2.2.1.1 Global Precision Medicine PCR Market (by Product) ........................... 145 8.2.2.1.2 Global Precision Medicine PCR Market (by End User) ......................... 146 8.2.2.1.3 Global Precision Medicine PCR Market (by Region) ............................ 147 8.2.2.2 Next-Generation Sequencing (NGS) ........................................... 148 All rights reserved at BIS Research 6

  7. Global Precision Medicine Market 8.2.2.2.1 8.2.2.2.2 8.2.2.2.3 8.2.2.2.4 8.2.2.3 8.2.2.3.1 8.2.2.3.2 8.2.2.3.3 8.2.2.4 8.2.2.4.1 8.2.3 8.2.3.1 Global Precision Medicine NGS Market (by Product) ........................... 150 Global Precision Medicine NGS Market (by Technology) ..................... 151 Global Precision Medicine NGS Market (by End User) ......................... 152 Global Precision Medicine NGS Market (by Region) ............................ 153 Genome Editing .......................................................................... 154 Global Precision Medicine Genome Editing Market (by Product) .......... 155 Global Precision Medicine Genome Editing Market (by End User) ....... 156 Global Precision Medicine Genome Editing Market (by Region) ........... 157 Other Technologies ..................................................................... 158 Global Precision Medicine Other Technologies Market (by Region) ..... 159 Pharmacogenomics ....................................................................... 160 Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services) .................................................... 165 Global Precision Medicine Pharmacogenomics Market (by End User) .................................................................................... 166 Global Precision Medicine Pharmacogenomics Market (by Region) ....................................................................................... 167 Other Applied Sciences ................................................................. 168 Precision Diagnostics ................................................................................... 169 8.3.1 Molecular Diagnostics (MDx)......................................................... 173 8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type) ......................................................................................... 176 8.3.2.1 Non-Invasive Prenatal Testing (NIPT) ......................................... 177 8.3.2.1.1 Global Precision Medicine NIPT Market (by Platform) .......................... 179 8.3.2.1.2 Global Precision Medicine NIPT Market (by Region) ............................ 180 8.3.2.2 Companion Diagnostics .............................................................. 181 8.3.2.2.1 Global Precision Medicine Companion Diagnostics Market (by Technology) ......................................................................................... 187 8.3.2.2.2 Global Precision Medicine Companion Diagnostics Market (by Indication) ............................................................................................ 188 8.3.2.2.3 Global Precision Medicine Companion Diagnostics Market (by Region) ................................................................................................ 189 8.3.2.3 Liquid Biopsy ............................................................................... 190 8.3.2.3.1 Global Precision Medicine Liquid Biopsy Market (by Indication) ........... 192 8.3.2.3.2 Global Precision Medicine Liquid Biopsy Market (by Region) ............... 193 8.3.2.4 Other Molecular Diagnostics ....................................................... 194 8.2.3.2 8.2.3.3 8.2.4 8.3 All rights reserved at BIS Research 7

  8. Global Precision Medicine Market 8.3.2.4.1 Global Precision Medicine Other Molecular Diagnostics Market (by Type) ................................................................................................... 195 Global Precision Medicine Other Molecular Diagnostics Market (by Region) ................................................................................................ 196 Medical Imaging.............................................................................. 197 Global Precision Medicine Medical Imaging Market (by Type) .... 200 Imaging Analytics ................................................................................. 201 Imaging Computer-Aided Detection (CADx) ......................................... 202 Global Precision Medicine Medical Imaging Market (by Region) ....................................................................................... 204 Digital Health and Information Technology ................................................ 205 8.4.1 Global Precision Medicine Digital Health and Information Technology Market (by Type) ........................................................ 206 8.4.1.1 Clinical Decision Support Systems (CDSS) ................................ 207 8.4.1.2 Big Data Analytics ....................................................................... 209 8.4.1.3 IT Infrastructure ........................................................................... 213 8.4.1.3.1 Global Precision Medicine IT Infrastructure Market (by Type) .............. 214 8.4.1.4 Genomics Informatics ................................................................. 215 8.4.1.4.1 Global Precision Medicine Genomics Informatics Market (by Product Type) ...................................................................................... 217 8.4.1.5 In-Silico Informatics ..................................................................... 219 8.4.1.6 Mobile Health .............................................................................. 221 8.4.2 Global Precision Medicine Digital Health and Information Technology Market (by End User)................................................. 223 8.4.3 Global Precision Medicine Digital Health and Information Technology Market, (by Region) ................................................... 224 Precision Therapeutics ................................................................................. 225 8.5.1 Global Precision Medicine Therapeutics Market (by Type) ........ 227 8.5.1.1 Clinical Trials ............................................................................... 228 8.5.1.1.1 Global Precision Medicine Clinical Trials Market (by Region) ............... 229 8.5.1.2 Cell Therapy ................................................................................ 230 8.5.1.2.1 Global Precision Medicine Cell Therapy Market (by Region) ................ 233 8.5.1.3 Drug Discovery and Research .................................................... 234 8.5.1.3.1 Global Precision Medicine Drug Discovery and Research Market (by Region), ......................................................................................... 236 8.3.2.4.2 8.3.3 8.3.3.1 8.3.3.1.1 8.3.3.1.2 8.3.3.2 8.4 8.5 All rights reserved at BIS Research 8

  9. Global Precision Medicine Market Gene Therapy ............................................................................. 237 Global Precision Medicine Drug Discovery and Research Market (by Region) .......................................................................................... 239 8.5.1.4 8.5.1.4.1 9.Global Precision Medicine Market (by Application) ............................................ 241 9.1 9.2 Overview ........................................................................................................ 241 Oncology........................................................................................................ 243 9.2.1 Cancer Precision Medicine Drugs and Indications ..................... 245 Infectious Diseases ....................................................................................... 247 9.3.1 Infectious Diseases Precision Medicine Drugs and Indications ...................................................................................... 249 Neurology ...................................................................................................... 250 9.4.1 Neurology Precision Medicine Drugs and Indications ................ 251 Cardiovascular .............................................................................................. 252 9.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications ...................................................................................... 254 Lifestyle and Endocrinology ........................................................................ 255 9.6.1 Endocrinology Precision Medicine Drugs and Indications ........ 256 Gastroenterology .......................................................................................... 257 9.7.1 Gastroenterology Precision Medicine Drugs and Indications .... 258 Other Applications ........................................................................................ 259 9.8.1 Precision Drugs for Other Applications ....................................... 261 9.3 9.4 9.5 9.6 9.7 9.8 10.Global Precision Medicine Market, (by Region) ................................................... 263 10.1Overview ........................................................................................................ 263 10.2North America ............................................................................................... 265 10.2.1 North America Precision Medicine Market (by Ecosystem) ....... 267 10.2.2 U.S. .................................................................................................. 269 10.2.2.1 Overview of Precision Medicine .................................................. 270 10.2.2.2 Key Trends .................................................................................. 271 10.2.2.3 Promoting Factors ....................................................................... 271 10.2.2.4 Recent Key Developments .......................................................... 271 10.2.2.5 Funding Scenario/Investments .................................................... 273 10.2.2.6 Regulatory Scenario .................................................................... 273 10.2.2.7 Key Players ................................................................................. 274 All rights reserved at BIS Research 9

  10. Global Precision Medicine Market Canada ............................................................................................ 274 Overview of Precision Medicine .................................................. 275 Key Trends .................................................................................. 276 Promoting Factors ....................................................................... 276 Recent Key Developments .......................................................... 276 Regulatory Scenario .................................................................... 277 Key Players ................................................................................. 277 10.3Europe ............................................................................................................ 278 10.3.1 Europe Precision Medicine Market (by Ecosystem) .................... 280 10.3.2 Germany .......................................................................................... 282 10.3.2.1 Overview of Precision Medicine .................................................. 283 10.3.2.2 Key Trends .................................................................................. 284 10.3.2.3 Promoting Factors ....................................................................... 284 10.3.2.4 Recent Key Developments .......................................................... 284 10.3.2.5 Key Players ................................................................................. 285 10.3.3 France .............................................................................................. 285 10.3.3.1 Overview of Precision Medicine .................................................. 286 10.3.3.2 Key Trends .................................................................................. 287 10.3.3.3 Promoting Factors ....................................................................... 287 10.3.3.4 Recent Key Developments .......................................................... 288 10.3.3.5 Key Players ................................................................................. 288 10.3.4 Italy .................................................................................................. 288 10.3.4.1 Overview of Precision Medicine .................................................. 290 10.3.4.2 Key Trends .................................................................................. 290 10.3.4.3 Promoting Factors ....................................................................... 290 10.3.4.4 Recent Key Developments .......................................................... 291 10.3.4.5 Funding Scenario/Investments .................................................... 291 10.3.5 U.K. .................................................................................................. 291 10.3.5.1 Overview of Precision Medicine .................................................. 292 10.3.5.2 Key Trends .................................................................................. 294 10.3.5.3 Promoting Factors ....................................................................... 294 10.3.5.4 Recent Key Developments .......................................................... 294 10.3.5.5 Funding Scenario/Investments .................................................... 294 10.2.3 10.2.3.1 10.2.3.2 10.2.3.3 10.2.3.4 10.2.3.5 10.2.3.6 All rights reserved at BIS Research 10

  11. Global Precision Medicine Market Key Players ................................................................................. 295 Spain ................................................................................................ 295 Overview of Precision Medicine .................................................. 297 Key Trends .................................................................................. 297 Promoting Factors ....................................................................... 298 Recent Key Developments .......................................................... 298 Key Players ................................................................................. 298 Rest-of-Europe................................................................................ 299 Switzerland.................................................................................. 300 10.4Asia-Pacific .................................................................................................... 302 10.4.1 Asia-Pacific Precision Medicine Market (by Ecosystem) ............ 305 10.4.2 China ............................................................................................... 307 10.4.2.1 Overview of Precision Medicine .................................................. 308 10.4.2.2 Key Trends .................................................................................. 309 10.4.2.3 Promoting Factors ....................................................................... 309 10.4.2.4 Recent Key Developments .......................................................... 309 10.4.2.5 Key Players ................................................................................. 309 10.4.3 Japan ............................................................................................... 310 10.4.3.1 Overview of Precision Medicine .................................................. 311 10.4.3.2 Key Trends .................................................................................. 311 10.4.3.3 Promoting Factors ....................................................................... 312 10.4.3.4 Recent Key Developments .......................................................... 312 10.4.3.5 Reimbursement Scenario ............................................................ 312 10.4.3.6 Key Players ................................................................................. 313 10.4.4 Australia .......................................................................................... 313 10.4.4.1 Overview of Precision Medicine .................................................. 314 10.4.4.2 Key Trends .................................................................................. 315 10.4.4.3 Promoting Factors ....................................................................... 315 10.4.4.4 Recent Key Developments .......................................................... 315 10.4.4.5 Regulatory Scenario .................................................................... 316 10.4.4.6 Key Players ................................................................................. 316 10.4.5 India ................................................................................................. 316 10.4.5.1 Overview of Precision Medicine .................................................. 318 10.3.5.6 10.3.6 10.3.6.1 10.3.6.2 10.3.6.3 10.3.6.4 10.3.6.5 10.3.7 10.3.7.1 All rights reserved at BIS Research 11

  12. Global Precision Medicine Market Key Trends .................................................................................. 319 Promoting Factors ....................................................................... 319 Recent Key Developments .......................................................... 319 Key Players ................................................................................. 320 Rest-of-Asia-Pacific (RoAPAC) ..................................................... 321 Singapore .................................................................................... 322 Regulatory Framework ......................................................................... 323 South Korea ................................................................................ 323 Vietnam ....................................................................................... 324 10.5Latin America ................................................................................................ 325 10.5.1 Latin America Precision Medicine Market (by Ecosystem) ........ 327 10.5.2 Brazil ................................................................................................ 329 10.5.2.1 Overview of Precision Medicine .................................................. 330 10.5.3 Mexico ............................................................................................. 331 10.5.3.1 Overview of Precision Medicine .................................................. 332 10.5.3.2 Recent Key Developments .......................................................... 333 10.5.4 Rest-of-Latin America (RoLA) ....................................................... 333 10.6Rest-of-the-World (RoW) .............................................................................. 335 10.6.1 Rest-of-the-World Precision Medicine Market (by Ecosystem) ..................................................................................... 336 10.6.1.1 Israel ........................................................................................... 338 10.6.1.2 Saudi Arabia................................................................................ 338 10.6.1.3 United Arab Emirates .................................................................. 339 10.6.1.4 South Africa................................................................................. 340 10.6.1.5 Russia ......................................................................................... 341 10.4.5.2 10.4.5.3 10.4.5.4 10.4.5.5 10.4.6 10.4.6.1 10.4.6.1.1 10.4.6.2 10.4.6.3 11.Company Profiles ................................................................................................... 342 11.1Overview ........................................................................................................ 342 11.2Abbott Laboratories ...................................................................................... 343 11.2.1 Company Overview ........................................................................ 343 11.2.2 Role of Abbott Laboratories in Global Precision Medicine Market .............................................................................................. 343 11.2.3 Financials ........................................................................................ 344 11.2.4 Key Insights About Financial Health of the Company ................ 347 All rights reserved at BIS Research 12

  13. Global Precision Medicine Market SWOT Analysis ............................................................................... 348 11.3Almac Group Ltd. .......................................................................................... 349 11.3.1 Company Overview ........................................................................ 349 11.3.2 Role of Almac Group Ltd. in Global Precision Medicine Market .............................................................................................. 349 11.3.3 SWOT Analysis ............................................................................... 350 11.4Amgen Inc. ..................................................................................................... 351 11.4.1 Company Overview ........................................................................ 351 11.4.2 Role of Amgen Inc. in Global Precision Medicine Market ........... 351 11.4.3 Financials ........................................................................................ 352 11.4.4 Key Insights about Financial Health of the Company ................. 354 11.4.5 SWOT Analysis ............................................................................... 355 11.5ANGLE plc ..................................................................................................... 356 11.5.1 Company Overview ........................................................................ 356 11.5.2 Role of ANGLE plc in Global Precision Medicine Market ........... 356 11.5.3 Financials ........................................................................................ 357 11.5.4 Key Insights about Financial Health of the Company ................. 359 11.5.5 SWOT Analysis ............................................................................... 360 11.6Astellas Pharma Inc. ..................................................................................... 361 11.6.1 Company Overview ........................................................................ 361 11.6.2 Role of Astellas Pharma Inc.in Global Precision Medicine Market .............................................................................................. 361 11.6.3 Financials ........................................................................................ 362 11.6.4 Key Insights about Financial Health of the Company ................. 363 11.6.5 SWOT Analysis ............................................................................... 364 11.7Astra Zeneca .................................................................................................. 365 11.7.1 Company Overview ........................................................................ 365 11.7.2 Role of Astra Zeneca in Global Precision Medicine Market ........ 365 11.7.3 Financials ........................................................................................ 366 11.7.4 SWOT Analysis ............................................................................... 369 11.8ASURAGEN INC. ........................................................................................... 370 11.8.1 Company Overview ........................................................................ 370 11.2.5 All rights reserved at BIS Research 13

  14. Global Precision Medicine Market Role of ASURAGEN Inc. in Global Precision Medicine Market .............................................................................................. 370 SWOT Analysis ............................................................................... 371 11.9Bio-Rad Laboratories, Inc. ............................................................................ 372 11.9.1 Company Overview ........................................................................ 372 11.9.2 Role of Bio-Rad Laboratories, Inc. in Global Precision Medicine Market ............................................................................. 372 11.9.3 Financials ........................................................................................ 373 11.9.4 SWOT Analysis ............................................................................... 376 11.10bioMérieux S.A. ............................................................................................. 377 11.10.1Company Overview ........................................................................ 377 11.10.2Role of bioMérieux SA. in Global Precision Medicine Market .... 377 11.10.3Financials ........................................................................................ 379 11.10.4SWOT Analysis ............................................................................... 382 11.11Bristol-Myers Squibb Company ................................................................... 383 11.11.1Company Overview ........................................................................ 383 11.11.2Role of Bristol-Myers Squibb Company in Global Precision Medicine Market ............................................................................. 383 11.11.3Financials ........................................................................................ 385 11.11.4Key Insights about Financial Health of the Company ................. 386 11.11.5SWOT Analysis ............................................................................... 387 11.12Cardiff Oncology ........................................................................................... 388 11.12.1Company Overview ........................................................................ 388 11.12.2Role of Cardiff Oncology in Global Precision Medicine Market .............................................................................................. 388 11.12.3Financials ........................................................................................ 390 11.12.4Key Insights About Financial Health of the Company ................ 391 11.12.5SWOT Analysis ............................................................................... 392 11.13CETICS Healthcare Technologies GmbH .................................................... 393 11.13.1Company Overview ........................................................................ 393 11.13.2Role CETICS Healthcare Technologies GmbH in Global Precision Medicine Market ............................................................ 393 11.13.3SWOT Analysis ............................................................................... 394 11.14Danaher Corporation .................................................................................... 395 11.8.2 11.8.3 All rights reserved at BIS Research 14

  15. Global Precision Medicine Market 11.14.1Company Overview ........................................................................ 395 11.14.2Role of Danaher Corporation in Global Precision Medicine Market .............................................................................................. 395 11.14.3Financials ........................................................................................ 396 11.14.4SWOT Analysis ............................................................................... 397 11.15Eli Lilly and Company Limited ..................................................................... 398 11.15.1Company Overview ........................................................................ 398 11.15.2Role of Eli Lilly and Company Limited in Global Precision Medicine Market ............................................................................. 398 11.15.3Financials ........................................................................................ 400 11.15.4SWOT Analysis ............................................................................... 402 11.16Epic Sciences, Inc. ........................................................................................ 403 11.16.1Company Overview ........................................................................ 403 11.16.2Role Epic Sciences, Inc. in Global Precision Medicine Market .............................................................................................. 403 11.16.3SWOT Analysis ............................................................................... 405 11.17F. Hoffmann-La Roche Ltd ........................................................................... 406 11.17.1Company Overview ........................................................................ 406 11.17.2Role of F. Hoffman-LA Roche Ltd in Global Precision Medicine Market ............................................................................. 406 11.17.3Financials ........................................................................................ 408 11.17.4Key Insights About Financial Health of the Company ................ 411 11.17.5SWOT Analysis ............................................................................... 412 11.18General Electric Company ............................................................................ 413 11.18.1Company Overview ........................................................................ 413 11.18.2Role of GE Corporation in Global Precision Medicine Market .............................................................................................. 413 11.18.3Financials ........................................................................................ 414 11.18.4Key Insights about Financial Health of the Company ................. 416 11.18.5SWOT Analysis ............................................................................... 417 11.19Gilead Sciences, Inc...................................................................................... 418 11.19.1Company Overview ........................................................................ 418 11.19.2Role of Gilead Sciences, Inc. in Global Precision Medicine Market .............................................................................................. 418 All rights reserved at BIS Research 15

  16. Global Precision Medicine Market 11.19.3SWOT Analysis ............................................................................... 420 11.20GlaxoSmithKline plc ..................................................................................... 421 11.20.1Company Overview ........................................................................ 421 11.20.2Role of GlaxoSmithKline Plc in Global Precision Medicine Market .............................................................................................. 421 11.20.3Financials ........................................................................................ 422 11.20.4Key Insights about Financial Health of the Company ................. 424 11.20.5SWOT Analysis ............................................................................... 425 11.21Illumina, Inc. .................................................................................................. 426 11.21.1Company Overview ........................................................................ 426 11.21.2Role of Illumina, Inc. in Global Precision Medicine Market......... 426 11.21.3Financials ........................................................................................ 428 11.21.4Key Insights About Financial Health of the Company ................ 430 11.21.5SWOT Analysis ............................................................................... 431 11.22Intomics A/S .................................................................................................. 432 11.22.1Company Overview ........................................................................ 432 11.22.2Role Intomics A/S in Global Precision Medicine Market ............. 432 11.22.3SWOT Analysis ............................................................................... 433 11.23Johnson & Johnson Services, Inc. .............................................................. 434 11.23.1Company Overview ........................................................................ 434 11.23.2Role of Johnson and Johnson in Global Precision Medicine Market .............................................................................................. 434 11.23.3Financials ........................................................................................ 435 11.23.4Key Insights about Financial Health of the Company ................. 436 11.23.5SWOT Analysis ............................................................................... 437 11.24Konica Minolta, Inc........................................................................................ 438 11.24.1Company Overview ........................................................................ 438 11.24.2Role of Konica Minolta, Inc. in Global Precision Medicine Market .............................................................................................. 438 11.24.3Financials ........................................................................................ 439 11.24.4SWOT Analysis ............................................................................... 440 11.25Laboratory Corporation of America Holdings ............................................ 441 11.25.1Company Overview ........................................................................ 441 All rights reserved at BIS Research 16

  17. Global Precision Medicine Market 11.25.2Role of Laboratory Corporation of America Holdings in Global Precision Medicine Market ................................................ 441 11.25.3Financials ........................................................................................ 442 11.25.4SWOT Analysis ............................................................................... 444 11.26MDx Health, Inc. ............................................................................................ 445 11.26.1Company Overview ........................................................................ 445 11.26.2Role of MDx Health, Inc. in Global Precision Medicine Market .............................................................................................. 445 11.26.3Financials ........................................................................................ 446 11.26.4SWOT Analysis ............................................................................... 447 11.27Menarini Silicon Biosystems, Inc. ............................................................... 448 11.27.1Company Overview ........................................................................ 448 11.27.2Role Menarini Silicon Biosystems, Inc. in Global Precision Medicine Market ............................................................................. 448 11.27.3SWOT Analysis ............................................................................... 450 11.28Merck KGaA ................................................................................................... 451 11.28.1Company Overview ........................................................................ 451 11.28.2Role of Merck KGaA in Global Precision Medicine Market ......... 451 11.28.3Financials ........................................................................................ 453 11.28.4Key Insights About Financial Health of the Company ................ 456 11.28.5SWOT Analysis ............................................................................... 457 11.29Myriad Genetics, Inc. .................................................................................... 458 11.29.1Company Overview ........................................................................ 458 11.29.2Role of Myriad Genetics, Inc. in Global Precision Medicine Market .............................................................................................. 458 11.29.3Financials ........................................................................................ 460 11.29.4Key Insights About Financial Health of the Company ................ 462 11.29.5SWOT Analysis ............................................................................... 463 11.30Novartis AG ................................................................................................... 464 11.30.1Company overview ......................................................................... 464 11.30.2Role of Novartis AG in Global Precision Medicine Market ......... 464 11.30.3Financials ........................................................................................ 466 11.30.4Key Insights about Financial Health of the Company ................. 469 11.30.5SWOT Analysis ............................................................................... 470 All rights reserved at BIS Research 17

  18. Global Precision Medicine Market 11.31Oracle Corporation........................................................................................ 471 11.31.1Company Overview ........................................................................ 471 11.31.2Role of Oracle Corporation in Global Precision Medicine Market .............................................................................................. 471 11.31.3Financials ........................................................................................ 472 11.31.4Key Insights about Financial Health of the Company ................. 474 11.31.5SWOT Analysis ............................................................................... 475 11.32Pacific Biosciences of California, Inc. ......................................................... 476 11.32.1Company Overview ........................................................................ 476 11.32.2Role of Pacific Biosciences of California, Inc. in Global Precision Medicine Market ........................................................... 476 11.32.3Financials ........................................................................................ 478 11.32.4Key Insights About Financial Health of the Company ................ 480 11.32.5SWOT Analysis ............................................................................... 481 11.33Partek, Inc. ..................................................................................................... 482 11.33.1Company Overview ........................................................................ 482 11.33.2Role Partek, Inc. in Global Precision Medicine Market ............... 482 11.33.3SWOT Analysis ............................................................................... 483 11.34Pfizer Inc. ....................................................................................................... 484 11.34.1Company Overview ........................................................................ 484 11.34.2Role of Pfizer, Inc. in Global Precision Medicine Market ............ 484 11.34.3Financials ........................................................................................ 486 11.34.4Key Insights about Financial Health of the Company ................. 489 11.34.5SWOT Analysis ............................................................................... 490 11.35QIAGEN N.V.* ................................................................................................. 491 11.35.1Company Overview ........................................................................ 491 11.35.2Role of QIAGEN N.V. in Global Precision Medicine Market ........ 491 11.35.3Financials ........................................................................................ 493 11.35.4Key Insights About Financial Health of the Company ................ 496 11.35.5SWOT Analysis ............................................................................... 497 11.36Quest Diagnostics Incorporated .................................................................. 498 11.36.1Company Overview ........................................................................ 498 All rights reserved at BIS Research 18

  19. Global Precision Medicine Market 11.36.2Role of Quest Diagnostics Incorporated in Global Precision Medicine Market ............................................................................. 498 11.36.3Financials ........................................................................................ 499 11.36.4SWOT Analysis ............................................................................... 500 11.37Randox Laboratories Ltd. ............................................................................. 501 11.37.1Company Overview ........................................................................ 501 11.37.2Role of Randox Laboratories Ltd. in Global Precision Medicine Market ............................................................................. 501 11.37.3SWOT Analysis ............................................................................... 502 11.38Sanofi S.A. ..................................................................................................... 503 11.38.1Company Overview ........................................................................ 503 11.38.2Role of Sanofi SA in Global Precision Medicine Market ............. 503 11.38.3Financials ........................................................................................ 505 11.38.4Key Insights about Financial Health of the Company ................. 508 11.38.5SWOT Analysis ............................................................................... 509 11.39Sysmex Corporation ..................................................................................... 510 11.39.1Company Overview ........................................................................ 510 11.39.2Role of Sysmex Corporation in Global Precision Medicine Market .............................................................................................. 510 11.39.3Financials ........................................................................................ 511 11.39.4Key Insights about Financial Health of the Company ................. 513 11.39.5SWOT Analysis ............................................................................... 514 11.40Teva Pharmaceuticals Industries Ltd. ......................................................... 515 11.40.1Company Overview ........................................................................ 515 11.40.2Role of Teva Pharmaceuticals Industries Ltd. in Global Precision Medicine Market ........................................................... 515 11.40.3Financials ........................................................................................ 516 11.40.4Key Insights about Financial Health of the Company ................. 518 11.40.5SWOT Analysis ............................................................................... 519 11.41Thermo Fisher Scientific Inc. ....................................................................... 520 11.41.1Company Overview ........................................................................ 520 11.41.2Role of Thermo Fisher Scientific Inc. in Global Precision Medicine Market ............................................................................. 520 11.41.3Financials ........................................................................................ 522 All rights reserved at BIS Research 19

  20. Global Precision Medicine Market 11.41.4Key Insights About Financial Health of the Company ................ 525 11.41.5SWOT Analysis ............................................................................... 526 All rights reserved at BIS Research 20

  21. Global Precision Medicine Market List of Figures List of Figures Figure 1: Precision Medicine: Treatment Tailored to an Individual’s Genetic Structure ....................... 40 Figure 2: Precision Medicine – a Multi-Faceted Approach to Patient Care........................................... 41 Figure 3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025) ........... 43 Figure 4: Impact Analysis of Market Drivers and Market Challenges on the Global Precision Medicine Market................................................................................................................................... 44 Figure 5: Global Precision Medicine Market (by Ecosystem), 2019 vs. 2030 ($Billion) ....................... 45 Figure 6: Global Precision Medicine Market (by Application Area), 2019 vs. 2030 ($Billion) ............... 46 Figure 7: Global Precision Medicine Market (by Region) Snapshot ...................................................... 47 Figure 1.1: Global Precision Medicine Market Segmentation ................................................................ 50 Figure 1.2: Global Precision Medicine Market Methodology ................................................................. 52 Figure 3.1: Primary Research Methodology ........................................................................................... 54 Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis) ................................................................. 56 Figure 4.1: Precision Medicine Approach ............................................................................................... 59 Figure 4.2: Evolution of Precision Medicine Technology ....................................................................... 60 Figure 4.3: Precision Medicine: Enabling Technologies and Applications ............................................ 67 Figure 4.4: Structured Big Data Reporting Benefits ............................................................................... 76 Figure 4.5: Generalized Process for the Microarray .............................................................................. 82 Figure 4.6: Global Precision Medicine Market: COVID-19 Impact ........................................................ 84 Figure 5.1: Impact Analysis ..................................................................................................................... 86 Figure 5.2: Percent of Patients Whose Tumor Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs.............................................................................................. 90 Figure 6.1: Patent Analysis ................................................................................................................... 101 Figure 6.2: Role of FDA in Advancing Precision Medicine .................................................................. 103 Figure 6.3: FDA Guidelines for CDx Approval ...................................................................................... 115 Figure 7.1: Share of Key Developments and Strategies, January 2012–July 2020 ........................... 118 Figure 7.2: Synergistic Activities (January 2012- July 2020) ............................................................... 120 Figure 7.3: Product launches, Enhancements, and Upgradation by Companies (January 2012-July 2020) .................................................................................................................................. 121 All rights reserved at BIS Research 21

  22. Global Precision Medicine Market Figure 7.4: Product Approvals by Companies (January 2012-July 2020) ........................................... 122 Figure 7.5: Merger and Acquisitions Share by Companies (January 2012-July 2020) ...................... 124 Figure 7.6: Business Expansion Share by Companies (January 2012-July 2020) ............................. 125 Figure 7.7: Market Share Analysis for PM Applied Sciences Ecosystem, 2019 ................................. 127 Figure 7.8: Market Share Analysis for PM Diagnostics Ecosystem, 2019 .......................................... 129 Figure 7.9: Market Share Analysis by PM Therapeutics Ecosystem, 2019 ........................................ 131 Figure 7.10: Market Share Analysis by PM Digital Health and IT Ecosystem, 2019 .......................... 133 Figure 7.11: Share of Key Developments and Strategies, January 2014–February 2020 ................. 134 Figure 8.1: Precision Medicine: The Ecosystem .................................................................................. 135 Figure 8.2: Global Precision Medicine Market (by Ecosystem) ........................................................... 137 Figure 8.3: Global Precision Medicine Market (by Ecosystem), 2019-2030 ....................................... 137 Figure 8.4: Global Precision Medicine Market (by Applied Sciences) ................................................. 138 Figure 8.5: Global Precision Medicine Market (by Applied Sciences), 2019-2030 ............................. 139 Figure 8.6: Precision Medicine: Multi-omics Sciences ......................................................................... 140 Figure 8.7: Global Precision Medicine Applied Sciences Market (by Type), 2019-2030 .................... 140 Figure 8.8: Precision Medicine: Genomics ........................................................................................... 141 Figure 8.9: Global Precision Medicine Genomics Market, 2019-2030 ................................................ 142 Figure 8.10: Global Precision Medicine Genomics Market (by Technology), 2019-2030 .................. 143 Figure 8.11: Global Precision Medicine PCR Market, 2019-2030 ....................................................... 144 Figure 8.12: Global Precision Medicine PCR Market (by Product ), 2019-2030 ................................. 145 Figure 8.13: Global Precision Medicine PCR Market (by End User), 2019-2030 ............................... 146 Figure 8.14: Global Precision Medicine PCR Market (by Region), 2019-2030 ................................... 147 Figure 8.15: Evolution of Next-Generation Sequencing....................................................................... 148 Figure 8.16: Global Precision Medicine NGS Market, 2019-2030 ....................................................... 149 Figure 8.17: Global Precision Medicine NGS Market (by Product), 2019-2030 ................................. 150 Figure 8.18: Global Precision Medicine NGS Market (by Technology), 2019-2030 ........................... 151 Figure 8.19: Global Precision Medicine NGS Market (by End User), 2019-2030 ............................... 152 Figure 8.20: Global Precision Medicine NGS Market (by Region), 2019-2030 .................................. 153 Figure 8.21: Global Precision Medicine Genome Editing Market, 2019-2030 .................................... 154 All rights reserved at BIS Research 22

  23. Global Precision Medicine Market Figure 8.22: Global Precision Medicine Genome Editing Market (by Product), 2019-2030 ............... 155 Figure 8.23: Global Precision Medicine Genome Editing Market (by End User), 2019-2030 ............ 156 Figure 8.24: Global Precision Medicine Genome Editing Market (by Region), 2019-2030 ................ 157 Figure 8.25: Global Precision Medicine Other Technologies Market, 2019-2030 .............................. 158 Figure 8.26: Global Precision Medicine Other Technologies Market (by Region), 2019-2030 ......... 159 Figure 8.27: Role of Biomarkers in Pharmacogenomics ..................................................................... 160 Figure 8.28: Role of FDA In Pharmacogenomics................................................................................. 163 Figure 8.29: Global Precision Medicine Pharmacogenomics Market, 2019-2030 .............................. 164 Figure 8.30: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2019-2030 .......................................................................................................................... 165 Figure 8.31: Global Precision Medicine Pharmacogenomics Market (by End User), 2019-2030 ...... 166 Figure 8.32: Global Precision Medicine Pharmacogenomics Market (by Region), 2019-2030 .......... 167 Figure 8.33: Global Precision Medicine Other Applied Sciences Market, 2019-2030 ........................ 168 Figure 8.34: Precision Medicine: Diagnostics ...................................................................................... 169 Figure 8.35: Global Precision Medicine Market (by Precision Diagnostics) ........................................ 170 Figure 8.36: Global Precision Medicine Market (by Precision Diagnostics), 2019-2030 .................... 170 Figure 8.37: Global Precision Medicine Diagnostics Market (by Type), 2019-2030 ........................... 172 Figure 8.38: General Workflow of a Molecular Diagnostic Assay........................................................ 174 Figure 8.39: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics) ................... 174 Figure 8.40: Global Precision Medicine Molecular Diagnostics Market, 2019-2030 .......................... 175 Figure 8.41: Global Precision Medicine Molecular Diagnostics Market (by Type), 2019-2030 ......... 176 Figure 8.42: Benefits and Risks Associated with NIPT ........................................................................ 178 Figure 8.43: Global Precision Medicine NIPT Market, 2019-2030 ...................................................... 178 Figure 8.44: Global Precision Medicine NIPT Market (by Platform), 2019-2030 ................................ 179 Figure 8.45: Global Precision Medicine NIPT Market (by Region), 2019-2030 .................................. 180 Figure 8.46: Drug and Companion Diagnostics Development Process .............................................. 182 Figure 8.47: Benefits and Risks Associated with Companion Diagnostics ......................................... 184 Figure 8.48: Global Precision Medicine Companion Diagnostics Market, 2019-2030........................ 186 All rights reserved at BIS Research 23

  24. Global Precision Medicine Market Figure 8.49: Global Precision Medicine Companion Diagnostics Market (by Technology), 2019-2030 .......................................................................................................................... 187 Figure 8.50: Global Precision Medicine Companion Diagnostics Market (by Indication), 2019-2030 188 Figure 8.51: Global Precision Medicine Companion Diagnostics Market (by Region), 2019-2030 .. 189 Figure 8.52: Clinical Applications of Liquid Biopsy ............................................................................... 190 Figure 8.53: Global Precision Medicine Liquid Biopsy Market, 2019-2030 ......................................... 191 Figure 8.54: Global Precision Medicine Liquid Biopsy Market (by Indication), 2019-2030 ................ 192 Figure 8.55: Global Precision Medicine Liquid Biopsy Market (by Region), 2019-2030 .................... 193 Figure 8.56: Global Precision Medicine Other Molecular Diagnostics Market, 2020-2030 ................ 194 Figure 8.57: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2019-2030 195 Figure 8.58: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2019-2030 .......................................................................................................................... 196 Figure 8.59: Global Precision Medicine Medical Imaging Market, 2019-2030 .................................... 199 Figure 8.60: Global Precision Medicine Medical Imaging Market (by Type), 2019-2030 ................... 200 Figure 8.61: Global Precision Medicine Imaging Analytics Market, 2019-2030 .................................. 201 Figure 8.62: Global Precision Medicine CADx Market, 2019-2030 ..................................................... 203 Figure 8.63: Global Precision Medicine Medical Imaging Market (by Region), 2019-2030................ 204 Figure 8.64: Global Precision Medicine Digital Health and Information Technology Market, 2019-2030 .......................................................................................................................... 205 Figure 8.65: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2019-2030 .......................................................................................................................... 206 Figure 8.66: Global Precision Medicine CDSS Market, 2019-2030 .................................................... 208 Figure 8.67: Big Data Attributes ............................................................................................................ 210 Figure 8.68: Global Precision Medicine Big Data Analytics Market, 2019-2030 ................................. 211 Figure 8.69: Big Data Analytics: Key Benefits ...................................................................................... 212 Figure 8.70: Global Precision Medicine IT Infrastructure Market, 2019-2030 ..................................... 213 Figure 8.71: Global Precision Medicine IT Infrastructure Market (by Type), 2019-2030 .................... 214 Figure 8.72: Global Precision Medicine Genomics Informatics Market, 2019-2030 ........................... 216 Figure 8.73: Global Precision Medicine Genomics Informatics Market (by Product Type), 2019-2030 .......................................................................................................................... 217 All rights reserved at BIS Research 24

  25. Global Precision Medicine Market Figure 8.74: Global Precision Medicine In-Silico Informatics Market, 2019-2030............................... 220 Figure 8.75: Global Precision Medicine Mobile Health Market, 2019-2030 ........................................ 222 Figure 8.76: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2019-2030 ................................................................................................. 223 Figure 8.77: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2019-2030 .......................................................................................................................... 224 Figure 8.78: Global Precision Medicine Therapeutics Market, 2019-2030 ......................................... 226 Figure 8.79: Global Precision Medicine Therapeutics Market (by Type), 2019-2030 ......................... 227 Figure 8.80: Global Precision Medicine Clinical Trials Market, 2019-2030 ......................................... 228 Figure 8.81: Global Precision Medicine Clinical Trials Market (by Region), 2019-2030 ..................... 229 Figure 8.82: Types of Cell Therapy....................................................................................................... 231 Figure 8.83: Global Precision Medicine Cell Therapy Market, 2019-2030 .......................................... 232 Figure 8.84: Global Precision Medicine Cell Therapy Market (by Region), 2019-2030...................... 233 Figure 8.85: Global Precision Medicine Drug Discovery and Research Market, 2019-2030 ............. 235 Figure 8.86: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030 .......................................................................................................................... 236 Figure 8.87: Types of Gene Therapy .................................................................................................... 237 Figure 8.88: Types of Gene Therapy .................................................................................................... 238 Figure 8.89: Global Precision Medicine Gene Therapy Market, 2019-2030 ....................................... 238 Figure 8.90: Global Precision Medicine Drug Discovery and Research Market (by Region), 2019-2030 .......................................................................................................................... 239 Figure 9.1: Global Precision Medicine Applications Market, 2019-2030 ............................................. 242 Figure 9.2: Types of Cancer .................................................................................................................. 243 Figure 9.3: Global Precision Medicine Oncology Market, 2019-2030 ................................................. 244 Figure 9.4: Global Precision Medicine Infectious Diseases Market, 2019-2030 ................................. 247 Figure 9.5: Number of Deaths by Top 18 Infectious Diseases, 2018 .................................................. 248 Figure 9.6: Global Precision Medicine Neurology Market, 2019-2030 ................................................ 250 Figure 9.7: Global Precision Medicine Cardiovascular Market, 2019-2030 ........................................ 253 Figure 9.8: Global Precision Medicine Lifestyle and Endocrinology Market, 2019-2030.................... 255 Figure 9.9: Global Precision Medicine Gastroenterology Market, 2019-2030 .................................... 257 All rights reserved at BIS Research 25

  26. Global Precision Medicine Market Figure 9.10: Global Precision Medicine Other Applications Market, 2019-2030 ................................ 260 Figure 10.1: Global Precision Medicine Market (by Region), 2019 and 2030..................................... 263 Figure 10.2: Global Precision Medicine Market (by Region), 2019-2030............................................ 264 Figure 10.3: North America Precision Medicine Market, 2019-2030 ................................................... 265 Figure 10.4: North America: Market Dynamics .................................................................................... 266 Figure 10.5: North America Precision Medicine Market (by Ecosystem), 2019-2030 ........................ 267 Figure 10.6: North America Precision Medicine Market (by Country), 2019-2030 ............................. 268 Figure 10.7: U.S. Precision Medicine Market, 2019-2030 ................................................................... 269 Figure 10.9: Europe Precision Medicine Market, 2019-2030 .............................................................. 278 Figure 10.10: Europe: Market Dynamics .............................................................................................. 279 Figure 10.11: Europe Precision Medicine Market (by Ecosystem), 2019-2030 .................................. 280 Figure 10.12: Europe Precision Medicine Market (by Country), 2019-2030 ....................................... 281 Figure 10.13: Germany Precision Medicine Market, 2019-2030 ......................................................... 282 Figure 10.14: France Precision Medicine Market, 2019-2030 ............................................................. 286 Figure 10.15: Italy Precision Medicine Market, 2019-2030 .................................................................. 289 Figure 10.16: The U.K. Precision Medicine Market, 2019-2030 .......................................................... 292 Figure 10.17: Spain Precision Medicine Market, 2019-2030 ............................................................... 296 Figure 10.18: Rest-of-Europe Precision Medicine Market, 2019-2030 ............................................... 299 Figure 10.19: Asia-Pacific Precision Medicine Market, 2019-2030 ..................................................... 302 Figure 10.20: APAC: Market Dynamics ................................................................................................ 304 Figure 10.21: Asia-Pacific Precision Medicine Market (by Ecosystem), 2019-2030 .......................... 305 Figure 10.22: Asia-Pacific Precision Medicine Market (by Country), 2019-2030 ................................ 306 Figure 10.23: China Precision Medicine Market, 2019-2030 ............................................................... 307 Figure 10.24: Japan Precision Medicine Market, 2019-2030 .............................................................. 310 Figure 10.25: Australia Precision Medicine Market, 2019-2030 .......................................................... 314 Figure 10.26: India Precision Medicine Market, 2019-2030 ................................................................ 317 Figure 10.27: Rest-of-Asia-Pacific Precision Medicine Market, 2019-2030 ........................................ 321 Figure 10.28: Latin America Precision Medicine Market, 2019-2030 .................................................. 325 Figure 10.29: APAC: Market Dynamics ................................................................................................ 326 All rights reserved at BIS Research 26

  27. Global Precision Medicine Market Figure 10.30: Latin America Precision Medicine Market (by Ecosystem), 2019-2030 ....................... 327 Figure 10.31: Latin America Precision Medicine Market (by Country), 2019-2030 ............................ 328 Figure 10.32: Brazil Precision Medicine Market, 2019-2030 ............................................................... 329 Figure 10.33: Mexico Precision Medicine Market, 2019-2030 ............................................................. 332 Figure 10.34: Rest-of-Latin America Precision Medicine Market, 2019-2030..................................... 334 Figure 10.35: Rest-of-the-World Precision Medicine Market (by Ecosystem), 2019-2030................. 336 Figure 10.36: Rest-of-the-World Precision Medicine Market, 2019-2030 ........................................... 337 Figure 11.1: Total Number of Companies Profiled ............................................................................... 342 Figure 11.2: Abbott Laboratories: Product Portfolio ............................................................................. 344 Figure 11.3: Abbott Laboratories: Overall Financials, 2017-2019 ....................................................... 344 Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2017-2019 .............................................. 345 Figure 11.5: Abbott Laboratories: Revenue (by Region), 2017-2019.................................................. 346 Figure 11.6: Abbott Laboratories: R&D Expenditure, 2017-2019 ........................................................ 347 Figure 11.7: Abbott Laboratories: SWOT Analysis .............................................................................. 348 Figure 11.8: Almac Group Ltd.: SWOT Analysis .................................................................................. 350 Figure 11.9: Abbott Laboratories: Product Portfolio ............................................................................. 352 Figure 11.10: Amgen Inc.: Overall Financials, 2017-2019 ................................................................... 352 Figure 11.11: Amgen Inc.: Revenue (by Region), 2018-2019 ............................................................. 353 Figure 11.12: Amgen Inc. R&D Expenditure, 2017-2019 .................................................................... 354 Figure 11.13: Amgen Inc.: SWOT Analysis .......................................................................................... 355 Figure 11.14: ANGLE plc: Overall Financials, 2017-2019 ................................................................... 357 Figure 11.15: ANGLE plc: Revenue (by Region), 2018-2019 ............................................................. 358 Figure 11.16: ANGLE plc R&D Expenditure, 2017-2019 ..................................................................... 359 Figure 11.17: ANGLE plc: SWOT Analysis .......................................................................................... 360 Figure 11.18: Astellas Pharma Inc.: Product Portfolio ......................................................................... 362 Figure 11.19: Astellas Pharma Inc.: Overall Financials, 2017-2019.................................................... 362 Figure 11.20: Astellas Pharma Inc. R&D Expenditure, 2017-2019 ..................................................... 363 Figure 11.21: Astellas Pharma Inc.: SWOT Analysis ........................................................................... 364 Figure 11.22: Astra Zeneca: Product Portfolio ..................................................................................... 366 All rights reserved at BIS Research 27

  28. Global Precision Medicine Market Figure 11.23: Astra Zeneca: Overall Financials, 2017-2019 ............................................................... 366 Figure 11.24: Astra Zeneca: Revenue (by Business Segment), 2017-2019....................................... 367 Figure 11.25: Astra Zeneca: Revenue (by Region), 2017-2019 .......................................................... 368 Figure 11.26: Astra Zeneca: SWOT Analysis....................................................................................... 369 Figure 11.27: ASURAGEN INC.: SWOT Analysis ............................................................................... 371 Figure 11.28: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019 ........................................... 373 Figure 11.29: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019................... 373 Figure 11.30: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019 ...................................... 374 Figure 11.31: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017 ............................................ 375 Figure 11.32: Bio-Rad Laboratories, Inc: SWOT Analysis ................................................................... 376 Figure 11.33: bioMérieux S.A.: Product Portfolio ................................................................................. 378 Figure 11.34: bioMérieux S.A.: Overall Financials, 2017-2019 ........................................................... 379 Figure 11.35: bioMérieux S.A.: Revenue (by Segment), 2017-2019................................................... 380 Figure 11.36: bioMérieux S.A.: Revenue (by Region), 2018-2019 ...................................................... 381 Figure 11.37: bioMérieux S.A.: SWOT Analysis .................................................................................. 382 Figure 11.38: Bristol-Myers Squibb Company: Product Portfolio ........................................................ 384 Figure 11.39: Bristol-Myers Squibb Company: Overall Financials, 2017-2019 .................................. 385 Figure 11.40: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017 .................................... 386 Figure 11.41: Bristol-Myers Squibb Company.: SWOT Analysis ........................................................ 387 Figure 11.42: Cardiff Oncology.: Product Portfolio ............................................................................... 389 Figure 11.43: Cardiff Oncology: Overall Financials, 2018-2019 .......................................................... 390 Figure 11.44: Cardiff Oncology: R&D Expenditure, 2018-2019........................................................... 391 Figure 11.45: Cardiff Oncology: SWOT Analysis ................................................................................. 392 Figure 11.46: CETICS Healthcare Technologies GmbH: SWOT Analysis ......................................... 394 Figure 11.47: Danaher Corporation: Overall Financials, 2017-2019 ................................................... 396 Figure 11.48: Danaher Corporation: Revenue (by Business Segment), 2017-2019 .......................... 396 Figure 11.49: Danaher Corporation: SWOT Analysis .......................................................................... 397 Figure 11.50: Eli Lilly and Company Limited: Product Portfolio ........................................................... 399 Figure 11.51: Eli Lilly and Company Limited: Overall Financials, 2017-2019 ..................................... 400 All rights reserved at BIS Research 28

  29. Global Precision Medicine Market Figure 11.52: Eli Lilly and Company Limited: Revenue (by Region), 2018-2019 ............................... 401 Figure 11.53: Eli Lilly and Company Limited: SWOT Analysis ............................................................ 402 Figure 11.54: Epic Sciences, Inc.: Product Portfolio ............................................................................ 404 Figure 11.55: Epic Sciences, Inc.: SWOT Analysis ............................................................................. 405 Figure 11.56: F. Hoffmann-La Roche Ltd: Product Portfolio................................................................ 407 Figure 11.57: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019 .......................................... 408 Figure 11.58: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019 ................................. 409 Figure 11.59: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019 .................................... 410 Figure 11.60: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019 .......................................... 411 Figure 11.61: F. Hoffmann-La Roche Ltd: SWOT Analysis ................................................................. 412 Figure 11.62: GE Healthcare: Product Portfolio ................................................................................... 414 Figure 11.63: General Electric Company: Overall Financials, 2017-2019 .......................................... 414 Figure 11.64: General Electric Company: Revenue Split for Healthcare, 2017-2019 ........................ 415 Figure 11.65: General Electric: Healthcare Revenue (by Region), 2017-2019 .................................. 416 Figure 11.66: General Electric Company: R&D Expenditure, 2017-2019 ........................................... 416 Figure 11.67: General Electric Company: SWOT Analysis ................................................................. 417 Figure 11.68: Gilead Sciences, Inc.: Product Portfolio......................................................................... 419 Figure 11.69: Gilead Science, Inc.: SWOT Analysis ............................................................................ 420 Figure 11.70: GlaxoSmithKline plc: Overall Financials, 2017-2019 .................................................... 422 Figure 11.71: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019 ........................................... 423 Figure 11.72: GlaxoSmithKline plc: Revenue (by Region), 2017-2019............................................... 424 Figure 11.73: GlaxoSmithKline plc: R&D Expenditure, 2017-2019 ..................................................... 424 Figure 11.74: GlaxoSmithKline plc: SWOT Analysis ........................................................................... 425 Figure 11.75: Illumina, Inc.: Product Portfolio ....................................................................................... 427 Figure 11.76: Illumina, Inc.: Overall Financials, 2017-2019 ................................................................. 428 Figure 11.77: Illumina, Inc.: Revenue (by Segment), 2017-2019 ........................................................ 428 Figure 11.78: Illumina, Inc.: Revenue (by Region), 2017-2019 ........................................................... 429 Figure 11.79: Illumina, Inc.: R&D Expenditure, 2017-2019 ................................................................. 430 Figure 11.80: Illumina, Inc.: SWOT Analysis ........................................................................................ 431 All rights reserved at BIS Research 29

  30. Global Precision Medicine Market Figure 11.81: Intomics A/S: SWOT Analysis ........................................................................................ 433 Figure 11.82: Illumina, Inc.: Product Portfolio ....................................................................................... 435 Figure 11.83: Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019 ............ 435 Figure 11.84: Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019 ............ 436 Figure 11.85: Johnson & Johnson Services, Inc.: SWOT Analysis ..................................................... 437 Figure 11.86: Konica Minolta, Inc.: Overall Financials, 2017-2019 ..................................................... 439 Figure 11.87: Konica Minolta, Inc.: Revenue (by Region), 2017-2019 ............................................... 439 Figure 11.88: Konica Minolta, Inc.: SWOT Analysis ............................................................................ 440 Figure 11.89: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019 ............ 442 Figure 11.90: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019 ... 443 Figure 11.91: Laboratory Corporation of America Holdings: Revenue (by Region), 2019 ................. 443 Figure 11.92: Laboratory Corporation of America Holdings: SWOT Analysis .................................... 444 Figure 11.93: MDx Health, Inc.: Overall Financials, 2017--2019 ......................................................... 446 Figure 11.94: MDx Health, Inc.: SWOT Analysis ................................................................................. 447 Figure 11.95: Menarini Silicon Biosystems, Inc.: SWOT Analysis....................................................... 450 Figure 11.96: Merck KGaA: Product Portfolio ...................................................................................... 452 Figure 11.97: Merck KGaA: Overall Financials, 2017-2019 ................................................................ 453 Figure 11.98: Merck KGaA: Revenue (by Segment), 2017-2019 ....................................................... 454 Figure 11.99: Merck KGaA: Revenue (by Region), 2017-2019 ........................................................... 455 Figure 11.100: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019 ................... 455 Figure 11.101: Merck KGaA: R&D Expenditure, 2017-2019 ............................................................... 456 Figure 11.102: Merck KGaA: SWOT Analysis ..................................................................................... 457 Figure 11.103: Myriad Genetics, Inc.: Product Portfolio ...................................................................... 459 Figure 11.104: Myriad Genetics, Inc.: Overall Financials, 2017-2019 ................................................. 460 Figure 11.105: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019 ........................ 461 Figure 11.106: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019 ................................................. 462 Figure 11.107: Myriad Genetics, Inc.: SWOT Analysis ........................................................................ 463 Figure 11.108: Novartis AG: Overall Product Portfolio......................................................................... 465 Figure11.109: Novartis AG: Overall Financials, 2017-2019 ................................................................ 466 All rights reserved at BIS Research 30

  31. Global Precision Medicine Market Figure 11.110: Novartis AG Net Revenue (by Business Segment), 2017-2019 ................................. 467 Figure 11.111: Novartis AG: Net Revenue (by Region), 2017-2019 ................................................... 468 Figure 11.112: Novartis AG: R& D Expense, 2017-2019 .................................................................... 469 Figure 11.113: Novartis AG: SWOT Analysis....................................................................................... 470 Figure 11.114: Oracle Corporation: Overall Financials, 2017-2019 .................................................... 472 Figure 11.115: Oracle Corporation: Revenue (by Region), 2017-2019 .............................................. 473 Figure 11.116: Oracle Corporation R&D Expenditure, 2017-2019 ...................................................... 474 Figure 11.118: Pacific Biosciences of California, Inc.: Overall Product Portfolio ................................ 477 Figure 11.119: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019 ....................... 478 Figure 11.120: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019 .............. 479 Figure 11.121: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019 ................. 480 Figure 11.122: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019 ........................ 480 Figure 11.123: Pacific Biosciences of California, Inc.: SWOT Analysis .............................................. 481 Figure 11.124: Partek, Inc.: SWOT Analysis ........................................................................................ 483 Figure 11.125: Pfizer Inc.: Overall Product Portfolio ............................................................................ 485 Figure 11.126: Pfizer Inc.: Overall Financials, 2017-2019 ................................................................... 486 Figure 11.127: Pfizer Inc.: Revenue (by Segment), 2017-2019 .......................................................... 487 Figure 11.128: Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019 ............................... 487 Figure 11.129: Pfizer Inc.: Revenue (by Region), 2017-2019 ............................................................. 488 Figure 11.130: Pfizer Inc: R&D Expenditure, 2017-2019 ..................................................................... 489 Figure 11.131: Pfizer Inc.: SWOT Analysis .......................................................................................... 490 Figure 11.132: QIAGEN N.V.: Portfolio ................................................................................................ 492 Figure 11.133: QIAGEN N.V.: Overall Financials, 2017-2019 ............................................................. 493 Figure 11.134: QIAGEN N.V.: Revenue (by Segment), 2017-2019 .................................................... 494 Figure 11.135: QIAGEN N.V.: Revenue (by Region), 2017-2019 ....................................................... 495 Figure 11.136: QIAGEN N.V.: R&D Expenditure, 2017-2019 ............................................................. 496 Figure 11.137: QIAGEN N.V.: SWOT Analysis .................................................................................... 497 Figure 11.138: Quest Diagnostics Incorporated: Overall Financials, 2017-2019 ............................... 499 Figure 11.139: Quest Diagnostics Incorporated: SWOT Analysis ....................................................... 500 All rights reserved at BIS Research 31

  32. Global Precision Medicine Market Figure 11.140: Randox Laboratories Ltd.: SWOT Analysis ................................................................. 502 Figure 11.141: Sanofi SA: Product Portfolio ......................................................................................... 504 Figure 11.142: Sanofi SA: Overall Financials, 2017-2019 ................................................................... 505 Figure 11.143: Sanofi SA: Revenue (by Segment), 2017-2019 .......................................................... 506 Figure 11.144: Sanofi SA: Revenue (by Region), 2017-2019 ............................................................. 507 Figure 11.145: Sanofi SA: R&D Expenditure, 2017-2019 .................................................................... 508 Figure 11.146: Sanofi SA: SWOT Analysis .......................................................................................... 509 Figure 11.147: Sysmex Corporation: Overall Financials, 2017-2019 .................................................. 511 Figure 11.148: Sysmex Corporation: Revenue (by Business Segment), 2018-2019 ......................... 512 Figure 11.149: Sysmex Corporation R&D Expenditure, 2017-2019 ................................................... 513 Figure 11.150: Sysmex Corporation: SWOT Analysis ......................................................................... 514 Figure 11.151: Teva Pharmaceuticals Industries Ltd.: Product Portfolio ............................................ 516 Figure 11.152: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019 ...................... 516 Figure 11.153: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019 ................. 517 Figure 11.154: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019 ........................ 518 Figure 11.155: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis .............................................. 519 Figure 11.156: Thermo Fisher Scientific Inc.: Product Portfolio .......................................................... 521 Figure 11.157: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019..................................... 522 Figure 11.158: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019 ............................ 523 Figure 11.159: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019 ............................... 524 Figure 11.160: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019 ..................................... 525 Figure 11.161: Thermo Fisher Scientific Inc.: SWOT Analysis ............................................................ 526 All rights reserved at BIS Research 32

  33. Global Precision Medicine Market List of Tables List of Tables Table 4.1: Initiatives and Programs ........................................................................................................ 62 Table 5.1: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030) ........... 89 Table 5.2: Estimated Number of Cancer Incident Cases for 2018 and 2040........................................ 91 Table 5.3: Policy and Guidance Documents from the U.S. FDA ........................................................... 97 Table 6.1: Pipeline Analysis (by Company) .......................................................................................... 105 Table 6.2: Pipeline Analysis (by Product) ............................................................................................. 107 Table 6.3: Precision Medicine Drugs Pipeline Analysis ....................................................................... 108 Table 8.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labeling ................. 161 Table 8.2: Key Approved Therapeutics with FDA-Mandated Companion Diagnostics Tests ........... 183 Table 8.3: List of FDA Approved Companion Diagnostics ................................................................... 184 Table 8.4: Commercially Available Primary and Secondary Analysis Tools Providers ...................... 219 Table 9.1: Cancer Precision Medicine Drugs and Indications ............................................................. 245 Table 9.2: Infectious Diseases Precision Medicine Drugs and Indications ......................................... 249 Table 9.3: Neurology Precision Medicine Drugs and Indications ........................................................ 251 Table 9.4: Cardiovascular Precision Medicine Drugs/Tests/ and Indications ..................................... 254 Table 9.5: Endocrinology Precision Medicine Drugs and Indications.................................................. 256 Table 9.6: Gastroenterology Precision Medicine Drugs and Indications ............................................. 258 Table 9.7: Precision Drugs for Other Applications ............................................................................... 261 Table 10.1: Funding scenario in Universities........................................................................................ 293 All rights reserved at BIS Research 33

  34. Global Precision Medicine Market BIS Research Offerings: BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Know More All rights reserved at BIS Research 34

  35. Global Precision Medicine Market Disclaimer Disclaimer BIS Research provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon several estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, and are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 All rights reserved at BIS Research 35

  36. Global Precision Medicine Market BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: info@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 All rights reserved at BIS Research 36

More Related